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Abstract
Summary Fracture liaison services (FLS) are advocated to
improve osteoporosis treatment after fragility fracture, but
there are few economic analyses of different models. A
population-based 1i [=type C] FLS for non-hip fractures was
implemented and it costs $44 per patient and it was very cost-
effective ($9200 per QALY gained). Small operational chang-
es would convert it from cost-effective to cost-saving.
Introduction After fragility fracture, <20% of patients receive
osteoporosis treatment. FLS are recommended to address this
deficit but there are very few economic analyses of different
FLS models. Therefore, we conducted an economic analysis
of a 1i (=type C) FLS called BCatch a Break (CaB).^
Methods CaB is a population-based FLS in Alberta, Canada,
that case-finds older outpatients with non-traumatic upper ex-
tremity, spine, pelvis, or Bother^ non-hip fractures and pro-
vides telephonic outreach and printed educational materials to
patients and their physicians. Cost-effectiveness was assessed
usingMarkov decision-analytic models. Costs were expressed
in 2014 Canadian dollars and effectiveness based on model
simulations of recurrent fractures and quality-adjusted life
years (QALYs). Perspective was healthcare payer; horizon
was lifetime; and costs and benefits were discounted 3%.
Results Over 1 year, CaB enrolled 7323 outpatients (mean
age 67 years, 75% female, 69% upper extremity) at average
cost of $44 per patient. Compared with usual care, CaB in-
creased rates of bisphosphonate treatment by 4.3 to 17.5%
(p < 0.001). Over their lifetime, for every 10,000 patients
enrolled in CaB, 4 hip fractures (14 fractures total) would be
avoided and 12 QALYs gained. Compared with usual care,
incremental cost-effectiveness of CaB was estimated at $9200
per QALY. CaB was cost-effective in 85% of 10,000 proba-
bilistic simulations. Sensitivity analyses showed if Bother^
fractures were excluded and intervention costs reduced 25%
that CaB would become cost-saving.
Conclusions A relatively inexpensive population-based 1i
(=type C) FLS was implemented in Alberta and it was very
cost-effective. If CaB excluded Bother^ fractures and de-
creased intervention costs by 25%, it would be cost-saving,
as would any FLS that was more effective and less expensive.
Keywords Cost-effectiveness analysis . Fracture liaison
services . Fragility fracture . Guidelines . Osteoporosis
treatment . Quality improvement
Introduction
Osteoporosis is a chronic and progressive condition associated
with low bone mineral density (BMD) and skeletal fragility
that causes susceptibility to low-trauma fragility fractures
[1–3]. Fractures can cause acute and chronic pain, deformity,
diminished quality of life, disability, loss of independence,
nursing home admission, and even death [1–3].
Osteoporosis affects at least two million Canadians or about
25% of women and 12% of men older than 50 years [2]. A
woman’s lifetime risk of an osteoporosis-related fracture is
40–50% while a man’s is 12–20% [2, 3]. Each year in
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Canada, there are about 130,000 osteoporosis-attributable
fractures at an estimated annual cost of $4.6 billion [4].
At present, many experts have described Ba crisis in the
treatment of osteoporosis^ and have noted that many of the
gains made in the last quarter of a century are unraveling [5].
This is particularly true for those who have just suffered an
osteoporosis-related fracture; instead of being the group with
the highest testing and treatment rates, those who have sur-
vived a fracture have rates of treatment of less than 20% [1,
5–9]. To address this care gap, clinicians, experts, and several
societies (e.g., American Society of Bone and Mineral
Research [ASBMR], International Osteoporosis Foundation
[IOF], Osteoporosis Canada [OC]) have strongly endorsed
fracture liaison services (FLS) that identify fracture patients
and alert their family physicians (1i [= type C]) and arrange
investigations such as BMD testing (2i [= type B]) and initiate
prescription treatments and longer-term follow-up (3i [= type
A]) [5–8]. Although there are a few randomized trials to
support FLS, the available evidence suggests that the more
intensive (and expensive) the FLS, the more effective it is at
managing osteoporosis and thus reducing downstream
fractures and improving quality of life [9]. There are,
however, even fewer data on whether different FLS models
are cost-effective or worthwhile [9, 10].
Thus, we undertook a detailed evaluation of BCatch a
Break (CaB),^ which is a B1i (= type C)^ population-based
outpatient FLS [11]. CaB itself was adapted from a random-
ized controlled trial of another 1i (= type C) intervention that
consisted of patient identification with telephonic contacts,
educational mail-outs, and patient-specific family physician
alerting and outreach that cost about $12 per patient
[12–15]. This intervention, tested under the ideal circum-
stances of a randomized trial, was cost-saving and a budget
impact analysis suggested it would Bbreak-even^ within
2 years of implementation [15]. In addition, another
Canadian province (Manitoba) conducted a randomized trial
comparing usual care controls to a similar 1i (= type C) strat-
egy as CaB (but used a different case-finding approach and
did not use telephonic outreach for patients) that costs about
$8 per patient and that was also cost-saving in formal econom-
ic analyses [16, 17]. But it should be acknowledged that both
of the aforementioned interventions [12–17] were conducted
as randomized trials under ideal circumstances and with ade-
quate resources and infrastructure, and it is well known that
when such evidence based on trials is translated into the Breal
world^ that implementation often suffers because of attenuat-
ed fidelity, that clinical effectiveness tends to diminish, and
that intervention costs may increase [1, 10].
Therefore, we undertook an independent economic evalu-
ation of CaB as it was introduced into the Breal world.^
Furthermore, although CaB is by strict definition a 1i (= type
C) FLS, it is still sufficiently different from other programs in
terms of the populations at risk, types of fractures included,
methods for determining eligibility, and the manner by which
specific intervention components are delivered that it requires
a comprehensive and independent evaluation to determine if it
should continue and if other jurisdictions should adopt some-
thing like CaB. We believe that a formal cost-effectiveness
analysis is still needed to better determine value for money
and return on investment for and hypothesized that the CaB
intervention would be superior to usual care.
Methods
Description of Catch a Break
Health Link is a pre-existing province-wide publicly funded
program for patient support and it proffers health advice and
counseling by trained staff. Health Link also has the infra-
structure to act as a platform for various health-related initia-
tives such as InformAlberta [18] and CaB. First, administra-
tive and claim data from emergency departments (ED) and
ambulatory urgent care centers across Alberta were reviewed
to identify patients who may have had a low-trauma (fragility)
non-hip fracture. Of note, patients with hip fractures (who are
hospitalized, undergo surgical fixation, spend weeks to
months in hospital or inpatient rehabilitation facilities, and
often transferred to long-term care) were deemed not suitable
for CaB because these patients are almost impossible to con-
tact within 6 weeks of fracture and need more intensive oste-
oporosis management [19]. Indeed, based on high-quality ran-
domized trials, guidelines recommend an inpatient-based
nurse case manager or orthogeriatric service (i.e., a 3i [= type
A]) to deal with frail and hospitalized hip fracture patients [2].
Thus, CaB was designed to help outpatients with non-
traumatic non-hip fractures.
Once patients were identified by administrative data, Health
Link staff contacted patients by phone 6 weeks post-fracture
and conducted a standardized osteoporosis screening risk
assessment using an electronic questionnaire [11, 19] similar
to FRAX or CAROC [2, 3]. Participants deemed Bhigh risk^
for osteoporosis and recurrent fracture (e.g., a 10-year risk of
major osteoporotic fracture = 20% or risk of hip fracture = 3%
[2, 3]) were asked to follow up with their family physician for
investigations and management of osteoporosis. Participants
were also mailed osteoporosis educational materials.
Notification of screening results, along with current diagnostic
and treatment guidelines, was sent to the family physician of
record. High-risk participants who had not yet seen their family
physician were contacted at 3 and 6 months with reminders.
All participants were contacted at 12 months to complete a
final assessment; this cohort represents the CaB intervention
group [19].
We stratified fractures into four groups: upper extremity (in-
cluding rib fractures since rates of low BMD and recurrent
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fracture are nearly identical to that of upper extremity fractures);
spine; pelvis (since rates of low BMD and recurrent fracture are
similar to that of hip fracture); and Bother^ (primarily ankle)
fractures [20]. For the mature CaB intervention running for
1 year, we determined that 4633 participants would complete
the intervention out of 7323 potentially eligible patients.
Using these same programmatic data, we also simulated a
control group (i.e., usual care) based on the outpatients enrolled
in CaB that were newly started on bisphosphonate treatment in
6–12 weeks after their non-traumatic non-hip fracture. Because
these outpatients had fracture, they were potentially eligible for
CaB, but since they were already newly treated, they did not
receive any further interventions or follow-up. They were oth-
erwise drawn from exactly the same population and have the
same age, sex, incident fracture distributions, and so on, as
those who entered CaB. For this control cohort, it was assumed
that rates of BMD tests, rates of low bone mass, rates of long-
term adherence and persistence with bisphosphonates, and all
downstream costs and event rates were the same as for the
patients who received the full CaB intervention and were
followed for 1 year. For between-group comparisons, chi-
squared and t tests as appropriate were used and a two-sided
p value of 0.05 was considered statistically significant.
Cost-effectiveness analysis
The cost-effectiveness analysis takes a third party healthcare
payor perspective and compares the group of outpatients with
fracture receiving the CaB intervention to a simulated usual
care control group by using a decision analytic model that
incorporates Markov processes. Data regarding population at
risk, fracture types, and achieved rates of treatment were
drawn directly from CaB. Cost-effectiveness was assessed
through a decision analytic model incorporating Markov pro-
cesses to estimate incremental costs and effectiveness based
on quality-adjusted life years (QALYs) gained [21–25]. In
general, interventions are considered cost-effective when they
either (1) cost less and are more effective or (2) cost more but
are more effective than a comparator, but society is willing to
pay for this additional cost. In the latter scenario, the incre-
mental cost-effectiveness ratio (ICER), the ratio of incremen-
tal cost to incremental health effect, is commonly compared to
some threshold level that reflects the amount a society is will-
ing to pay for an additional unit of health [26]. This threshold
represents the opportunity cost, relating to health outcomes
foregone, by the reallocation of resources needed for the in-
tervention [27]. A QALY-based threshold of $50,000 USD
(about $55,000 in 2014 $CDN [28]) is often suggested [29]
while a UK study [27] empirically estimated a threshold of
£12,936 (about $24,000 in 2014 $CDN); we used these
thresholds in our assessments of societal Bwillingness-to-
pay.^We took a lifetime horizon and the perspective of a third
party public healthcare payer.
Decision analytic model
Figure 3 illustrates the model, displaying two study arms and,
for each arm, four osteoporosis-related diagnosis and treat-
ment pathways possible in 12 months following fracture.
The proportion of patients within each group was derived
from CaB data (Table 1). Then, three unique Markov process-
es were constructed (Fig. 3), and these were distinguished
only by their transition probabilities: low bone mass and re-
ceiving osteoporosis treatment (M1), low bone mass detected
but not receiving osteoporosis treatment (M2), and normal
bone mass and appropriately not treated (M3). M1 and M3
represent high-quality guideline-concordant care.
The structure of the Markov process was adapted from the
IOF cost-effectiveness reference model [23–25] and our prior
work [14–16]. The model incorporates 15 health states that
simulate the movement of patients from the time of fracture
identification at age 50 years to the age of 100 years or death
(see Fig. 4). All patients entered the model at one of four initial
post-fracture health states (upper extremity, spine, pelvis, oth-
er) derived from CaB data. Then, a proportion of the cohort
moves to one of the other 11 states once per annual cycle, in
accordance with transition probabilities derived from rates
specific to the type of subsequent fracture incurred, presence
or absence of low bone mass, treatment induced and fracture
type-specific reductions in subsequent fractures, and
population-based and age-specific death rates.
Model assumptions
The model incorporates three simplifying assumptions. First,
patients were considered to have normal (T-scores better than or
equal to −1.1 at all skeletal sites measured) or treatably low
levels of bone mass (T-scores worse than −1.1, encompassing
densitometric osteopenia and osteoporosis) based on BMD
measurements. Second, we assumed all patients were treated
with alendronate or risedronate (hereafter referred to as bis-
phosphonate treatment), because they are generic and the most
widely prescribed bisphosphonates in Canada and have the
greatest weight of evidence available for fracture reduction.
Last, we assumed that no additional non-hip fractures would
Table 1 Distribution of patients by sub-group and study arm
Sub-group CaB intervention (%) Control (%)
LBM, Rx 17.5 13.2
LBM, no Rx 19.9 24.2
NBM 62.6 62.6
Total 100.0 100.0
LBM low bone mass, NBM normal bone mass, Rx treated with a
bisphosphonate
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occur after a hip fracture, although repeat hip fractures were
permitted [23–25].
Model inputs
The mean values and standard errors of all parameters used in
the model are presented in Table 5. The key inputs are sum-
marized below:
1. Repeat fracture rates.We assumed repeat fracture rates for
low bone mass patients not treated for osteoporosis were
constant with respect to age and fracture site [22–25] and
(because there are currently no comparable Alberta-based
data) based these fracture rates on recent Manitoba data
[18, 30]. Repeat fracture rates for normal bone mass were
considered to be the same as for patients with low bone
mass treated with bisphosphonates.
2. Fracture reduction with bisphosphonates. Estimates of
fracture reduction were based on meta-analysis and in-
cluded a pooled 49% reduction in risk of hip and vertebral
fractures and a pooled 48% reduction for humeral and
distal radial fractures [31]. In the base case analysis, bis-
phosphonate treatment was for 5-year duration. In the first
year of treatment, fracture reduction was assumed to be
half the full achievable benefit accrued over 5 years. As
well, a residual positive effect of treatment was assumed
for 5 years following discontinuation [32]. This residual
effect was modeled as linear but with diminishing benefits
[32]. One-year persistence with bisphosphonate treatment
has been reported as 60% [33], and we assumed this rate
of persistence would continue for the next 4 years of treat-
ment. All patients who persisted with bisphosphonate
treatment were assumed to have greater than 80% adher-
ence to their medications [15]. We assumed no clinical
benefits accrued to the 40% of patients who discontinued
treatment in the first year of treatment, and we assumed no
clinical benefits associated with over-the-counter calcium
and vitamin D supplements. For the latter, we also
assumed no costs as these supplements are not covered
and patients pay out of pocket.
3. Costs. All costs were expressed in constant 2014 CDN dol-
lars and restricted to direct medical costs, i.e., no indirect
costs were incorporated into our analyses. In the base case,
all costs and outcomes were discounted at 3% per annum
[34]. Specific costs included the following (for additional
details and information sources, also refer to Table 5):
& Costs of the CaB intervention. Ongoing costs for
case-finding and implementing the intervention were
based on independently conducted time-motion stud-
ies and shown in Table 2. Salary, benefits, and over-
head costs related to Health Link callers were includ-
ed. Ongoing programming (identifying patients and
creating mailing lists), administration (mailing, con-
sultants), and other supplies and postage were also
included. The cost per patient receiving the interven-
tion was $44. Initial programming costs related to
development and testing of the list generating algo-
rithm, database and telephone setup, and one-time
training costs were excluded.
& Costs of osteoporosis treatment. We assumed all pa-
tients treated with a bisphosphonate received 70 mg
per week of generic alendronate or 35 mg per week
of generic risedronate. Total annual cost of medication
and one annual osteoporosis-related primary care phy-
sician visit for re-evaluation and prescription refills
plus dispensing fees was $203 per patient [35, 36].
We also assumed bisphosphonates would generate
trivial direct medical costs related to side effects [37].
& Costs of subsequent fractures. Estimated annual costs
for the health states relate to the management of sub-
sequent clinically symptomatic spine, hip (including
pelvis fractures), and upper extremity fractures (in-
cluding rib). Costs were estimated based on standard-
ized physician fees while other health services and
their unit values were obtained from regional and na-
tional databases [36, 38]. We assumed hip fractures
Table 2 Intervention cost per
patient Cost item Cost per patient
a
Calling—no contact—could not be reached 1.98
Calling—contacted—declined 1.39
Calling—incomplete initial survey (patients not eligible for intervention) 2.55
Calling—patient eligible for intervention—all surveysb 24.45
Patient and physician packages (mail and email—sent by callers) 13.45
Programming—lists for callers 0.34
Consulting osteoporosis specialist 0.18
Average cost—patients receiving intervention 44.34
a Caller cost per minute = $0.70; 2014 Canadian dollars (multiply by 0.905 to convert to 2014 US dollars [28])
b Includes cost of unsuccessful call attempts
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would require surgical fixation and a 7-day hospital
stay [38]. A case-mix method was used for inpatient
costs [39]. It was assumed that 80% of patients would
be discharged home after hip fracture and 20% to
long-term care facilities; costs of long-term care were
based on provincial per diems less patient co-
payments [40]. Only 10% of patients with clinically
symptomatic vertebral fractures were assumed to re-
quire inpatient care [41]. Hospital costs were estimat-
ed in similar manner as hip fractures [38, 39].
Following discharge, routine care was considered
nine follow-up physician visits and one spinal radio-
graph. The non-hospitalized clinically symptomatic
vertebral fracture patients (90%) required four physi-
cian visits, two spinal radiographs, and eight visits of
outpatient rehabilitation. Patients with subsequent
proximal humerus and distal radius fractures were
assumed to present to EDs or fracture clinics for treat-
ment and had one closed fracture reduction, two phy-
sician follow-up visits, two post-reduction radio-
graphs, eight outpatient rehabilitation visits, and no
subsequent surgical repair.
4. Mortality rates. Patients were assumed to have the same
risk of death as the general population, except in the 1 year
following a hip fracture [22, 23]. Published life tables
were used for age-specific death rates [42], and age-
specific excess mortality rates in the 1 year following
hip fracture (and spine fracture) were derived from the
IOF reference models [25].
5. Health-related quality of life. We used age-specific utility
weights for each health state based on published utilities
and their proposed multipliers [25, 43].
Deterministic sensitivity analyses
Conventional one-way deterministic sensitivity analyses were
conducted to evaluate the robustness of the model. First, we
evaluated the impact of excluding Bother^ fractures fromCaB.
Collectively, these Bother^ fractures are not independently as-
sociated with an increased risk of subsequent fragility frac-
tures or low bone mass [20]. Second, we assessed the conse-
quences of a 25% decrease (or increase) in the intervention
cost. Third, although bisphosphonates are commonly used as
the base case analyses in many osteoporosis-related cost ef-
fectiveness models [44], other more expensive or Bon patent^
oral bisphosphonates (e.g., ibandronate) might be used; thus,
we conducted sensitivity analyses wherein drug costs were
doubled and tripled. Fourth, we re-ran our models assuming
only 35% fracture reduction with bisphosphonates; this is the
value used by the IOF [25] and approximates the lower
bounds of published 95% confidence intervals [31]. Fifth,
we included an analysis of the impact of 50% medication
adherence rather than the 80% adherence used in the base case
and employed recent projections that estimated bisphospho-
nate effectiveness would thence be only 30% of what could be
achieved with optimal adherence [44, 45]. Sixth, we explored
the impact of reducing the proportion of patients who
persisted with their medication from 60 to 30%. Seventh, be-
cause patients may derive a mortality reduction with
bisphosphonates, we included a sensitivity analysis to assess
an 11% bisphosphonate-related mortality reduction 1 year
post-fracture [46]. Eighth, we included the potential for in-
creased mortality following a vertebral fracture and handled
it in the same way we incorporated increased mortality after a
hip fracture. Ninth, although we used the currently recom-
mended 3% discount rate for both costs and benefits [34],
we examined the impact of using higher and lower discount
rates. Last, we conducted a two-way sensitivity analysis that
simultaneously excluded Bother^ fractures and reduced inter-
vention costs by 25% as these are the two aspects of the in-
tervention that healthcare administrators could change.
Probabilistic sensitivity analysis
We also conducted a probabilistic sensitivity analysis to assess
the impact of parameter uncertainty. Probability distributions
were assigned to all variables for which there was uncertainty
associated with the base case. We chose a gamma distribution
to generate random values for unit costs but otherwise used a
beta distribution and then undertook 10,000 simulations.
Results were summarized using a cost-effectiveness accept-
ability curve, which represents the percent of simulations that
were cost-effective for each study arm at various potential
levels of societal willingness-to-pay. All analyses were con-
ducted using the TreeAge Pro Healthcare Module 2016
(TreeAge Software Inc., Williamstown, MA).
Results
Patient characteristics
At baseline, the average age of eligible patients (n = 7323) was
67 (±11) years and 75%were female. Most (69%) patients had
an initial upper extremity fracture (including 14% with rib
fractures considered Bupper extremity equivalents^), 5% a
spine fracture, 4% a pelvis fracture (considered Bhip fracture
equivalents^), and 22% Bother^ fractures (17% ankle).
CaB intervention effect
Overall, CaB increased the proportion of patients who appro-
priately received bisphosphonate treatment to prevent future
fracture by 4.3%. Specifically, in the year following fracture,
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17.5% (95% CI 15.6–19.4%) of CaB patients were treated
with bisphosphonates vs 13.2% (95% CI 12.4–14.0%) of the
usual care control group (p < 0.001 for difference).
Base case analysis
The base case model suggests that, over their lifetime, patients
exposed to the CaB intervention would be less likely to
fracture again compared with usual care. For every 10,000
patients that participated in CaB, an additional 400 patients
would be treated with bisphosphonates, resulting in the avoid-
ance of about 4 hip fractures and 14 major osteoporotic frac-
tures in total and a modest gain of 12 QALYs vs usual care
(Table 3). Those gains were achieved at an incremental cost of
$11 per patient compared to usual care or about $9200 per
QALY gained.
Table 3 Costs and health
outcomes per patient by study
arm—CaB base case








Intervention 20,554 0.0990 0.3661 16.6949




11 −0.0004 −0.0014 0.0012
ICERe 9167
a Lifetime average costs per patient, discounted at 3%. These costs are expressed in constant 2014 Canadian
dollars (multiply by 0.905 to convert to 2014 US dollars [28])
b Refers to incident hip fractures per patient
c Includes hip, clinical vertebral, and upper extremity re-fractures per patient
d Average quality-adjusted life years per patient, discounted at 3%
e ICER: Incremental Cost-effectiveness Ratio = Incremental Cost/Incremental QALYs
Table 4 Deterministic sensitivity
analyses Scenario Incremental Cost
a Incremental Effect ICERa
Base case 11 0.0012 9167
Exclude Bother^ fractures 0 0.0014 0
Intervention costs
25% decrease 0 0.0012 0
25% increase 22 0.0012 18,440
Persistence with treatment
30%, rather than 60% 34 0.0006 56,667
Adherence with treatment
50%, rather than 80% 57b 0.0004 142,500
Bisphosphonate price
100% increase 31 0.0012 25,833
200% increase 51 0.0012 42,500
500% increase 111 0.0012 92,500
Effect of bisphosphonate 35% fracture reduction 31 0.0008 38,750
Discount rate (rather than 3%)
0% discount rate −30 0.0020 nab
1% discount rate −13 0.0016 nab
5% discount rate 26 0.0009 28,889
Mortality benefit (11% reduction) 12 0.0021 5714
Increased mortality 1 year post-spine fracture 11 0.0013 8462
QALYs quality-adjusted life years, ICER incremental cost-effectiveness ratio
a Costs are expressed in constant 2014 Canadian dollars (multiply by 0.905 to convert to 2014 US dollars [28])




One-way sensitivity analyses indicated that the results of the
base case were reasonably robust to most plausible scenarios,
i.e., achieving either an ICER of less than $55,000 or domi-
nating usual care (that is, less costly and more effective, see
Table 4). The three exceptions were a 500% increase in bis-
phosphonate price, reduction of treatment persistence to 30%
(from the base case of 60%), and assuming only 50% adher-
ence to treatment among those who persisted with treatment
for at least 1 year (vs base case of 80%, see Table 4).
Of note, there are some scenarios over which CaB admin-
istrators might have direct influence and could improve cost-
effectiveness. Namely, if Bother^ fractures were excluded
from case-finding, then incremental costs would be reduced
to 0, while the incremental effectiveness would improve
slightly. Similarly, decreasing intervention costs by 25% by
reducing the time spent on detailed risk assessment could also
reduce incremental cost to 0. Indeed, the two-way sensitivity
analysis showed, by simultaneously excluding Bother^ frac-
tures and reducing intervention costs by 25%, that incremental
cost would decline to −$11 per patient (i.e., CaB would be
cost-saving) and the incremental effect could increase to
0.0014 QALYs. Thus, instead of being very cost-effective,
the CaB intervention would in fact Bdominate^ usual care.
Probabilistic sensitivity analysis
The majority of simulations (71%) fell in Quadrant I (Fig. 1),
indicating that the intervention costs more than the usual care
but was also more effective. The remainder of the simulations
(29%) fell into Quadrant IV, indicating that the intervention
was dominant, i.e., less costly and more effective than usual
care. The cost-effectiveness acceptability curve for the inter-
vention (red curve Fig. 2) indicates that the intervention would
not be cost-effective if society’s willingness-to-pay was set at
0, i.e., the intervention must be cost-neutral or cost-saving to
be adopted. At the origin, where the threshold is 0, the prob-
ability that the intervention is cost-effective is only 29%.
However, the estimated ICER for the intervention is $9167
and lower than either of the thresholds described earlier.
Specifically, based on the uncertainty contained in our model,
the probability of the intervention being cost-effective is 64%
in relation to the $24,000 threshold (B), but 85% if the
$55,000 threshold (C) were deemed appropriate.
Quadrant IQuadrant II
Quadrant III Quadrant IV




Catch a Break is an ongoing evidence-informed 1i (=type C)
FLS intervention designed to identify patients with fragility
fracture at high risk of osteoporosis and alert both the patient
and their family physician to the need for more urgent man-
agement of osteoporosis. Based on earlier randomized trials
and recent meta-analysis, CaB would be expected to increase
osteoporosis treatment rates by about 16% (95%CI 7–25);
when implemented in the real world on a population-wide
basis, CaB increased treatment rates by about 4% at a cost
of approximately $44 per patient. Though it was both some-
what less effective and somewhat more expensive than prior
reports of similar interventions, our economic analysis sug-
gests that the program is still cost-effective. Specifically, for
every 10,000 participants who entered CaB, we would expect
to prevent 14 major osteoporotic fractures (4 fewer hip frac-
tures) and gain 12 additional QALYs at a cost of $9167 per
QALY gained. These findings were robust to numerous deter-
ministic and probabilistic sensitivity analyses and CaB would
be considered cost-effective in more than 80% of simulations
at conventional societal willingness-to-pay thresholds.
These findings were, analytically, most sensitive to as-
sumptions related to treatment (its costs, adherence, and per-
sistence) and discounting rates. On the other hand, in terms of
what those who actually run CaB have influence over, we
found that by reducing intervention costs by 25% (perhaps
by decreasing efforts on detailed osteoporosis risk assess-
ments) or excluding patients with Bother^ fractures (consistent
with available evidence [20] and other programs [16, 17]) or
Notes 
Line A indicates the ICER of the base case results.
Line B indicates the cost-effectiveness threshold based on Claxton[27]. 





acceptability curve. Notes: Line A
indicates the ICER of the base
case results. Line B indicates the
cost-effectiveness threshold based
on Claxton [27]. Line C indicates
the cost-effectiveness threshold
based on Neumann [29]
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doing both simultaneously would improve cost-effectiveness
substantively; the latter approach would yield cost-savings
and CaB would dominate usual care.
Although it is difficult to compare different interventions
and programs in terms of their cost-effectiveness, there are at
least four similar Canadian programs (or trials) [14–16, 47].
Three of the interventions were similar in structure to CaB,
although all three of these studies demonstrated greater effec-
tiveness in terms of increasing treatment rates and (on a per
patient basis) cost less than the CaB approach, and all three of
these studies were cost-saving and would Bbreak even^within
2–4 years of implementation [14–16]. The other study, the
Ontario Fracture Clinic Screening program [47], was more
effective at increasing treatment than CaB (increasing treat-
ment rates by about 20% vs usual care) but also costs more
than twice per patient of what CaB costs ($97 vs $44) and so it
was less cost-effective at $19,132 per QALY gained [47]. But
this is still Bcost-effective^ by conventional standards, and
those authors reported that if their program were enabled to
order BMD tests and send the results to family physicians
(Bfast track,^ essentially converting their 1i [= type C] model
to a 2i [= type B] model), it would be even more cost-effective
($5720 per QALY gained) [47].
Despite some strengths, there are several limitations of our
work that ought to be noted. First and foremost, our estimates
of effectiveness are not based on randomized trial evidence but
rather based on 1 year of follow-up ofCaBparticipants compared
with usual care simulations. That said, the estimate of effect is
actually smaller than that predicted by meta-analysis (95%CI
ranging from 7 to 25%), suggesting the absence of any over-
inflation of benefits that might be encountered in an uncontrolled
study. Second, although not a limitation of our economic analysis
per se, patients hospitalized with hip fractures were excluded
altogether and we do not know participant’s BMD or what their
long-term rates of recurrent fracture are as we only had 1 year of
programmatic data and not lifetime data. Third, all assumptions
that we made, by design, were very conservative (e.g., no mor-
tality benefit from bisphosphonates, no increased bone loss over
time without treatment, no mortality reduction associated with
preventing vertebral fractures) and biased against the interven-
tion, and this is perhaps best exemplified by our choice of dis-
count rate. Although we used the recommended real discount
rate of 3% [34], we believe this is quite high in the present low
interest rate environment. Since the stream of costs related to the
intervention is more weighted toward the present than usual care,
a lower discount rate (e.g., 1%) would result in the intervention
dominating usual care. Fourth, we did not include up-front setup
or training costs for CaB on the one hand nor on the other hand
did we include indirect costs such as lost productivity or informal
caregiving. Last, even though population-based and consistent
with 1i (= type C) FLS endorsed by ASBMR, IOF, and OC,
some may be concerned that the results may not be applicable
to other nations or jurisdictions.
In conclusion, a population-based implementation of a 1i
(=type C) FLS improved treatment of patients with osteoporo-
sis and over the long run would be expected to reduce recurrent
fractures, increase quality of life, and be cost-effective under a
wide range of assumptions and across different societal thresh-
olds for willingness to pay. More effective and less expensive
programswould be expected to be evenmore cost-effective and
perhaps even cost-saving, but this remains to be seen.
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Fig. 3 Decision tree of the model with Markov processes. Probabilities
associated with each chance node are shown under the relevant branch.
LBM indicates low bone mass; NBM, normal bone mass; and Rx,
treatment with a bisphosphonate. M1, M2, and M3 refer to the
individual Markov processes; also, see the BMethods^ section and Fig. 2
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Fig. 4 Structure of the Markov process. Adapted from references
[23–25]. There are potential transitions from each health state to the
dead state that are not shown in the figure, for purposes of clarity. As
well, patients can remain in all states for multiple cycles. The Post-Upper
Extremity Fx state includes Rib Fx. The Post-Other Fx state includes
Ankle Fx
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Distribution type for PSA
Source
Prior probabilities
Probability of Rx treatment intervention arm 0.469 (0.021) Beta 19
Probability of Rx treatment control arm 0.352 (0.016) Beta 19
Probability of low bone mass 0.374 (0.012) Beta 19
Initial health state proportions
Post-upper extremity fracture 0.691 (0.005) Beta 19
Post-spine fracture 0.051 (0.003) Beta 19
Post-pelvis fracture 0.043 (0.002) Beta 19
Post-other fracture 0.215 (0.005) Beta 19
Re-fracture probabilities
Prior upper extremity fracture
Upper extremity fracture 0.007 (0.001) Beta 17, 30
Spine fracture 0.006 (0.001) Beta 17, 30
Hip fracture 0.004 (0.001) Beta 17, 30
Prior spine fracture
Upper extremity fracture 0.011 (0.003) Beta 17, 30
Spine fracture 0.004 (0.001) Beta 17, 30
Hip fracture 0.007 (0.002) Beta 17, 30
Prior pelvis/hip fracture
Upper extremity fracture 0.017 (0.004) Beta 17, 30
Spine fracture 0.010 (0.003) Beta 17, 30
Hip fracture 0.014 (0.004) Beta 17, 30
Prior other fracture
Upper extremity fracture 0.002 (0.0002) Beta 17, 30
Spine fracture 0.002 (0.0001) Beta 17, 30
Hip fracture 0.001 (0.0001) Beta 17, 30
Relative risk of fracture following treatment
Spine fracture 0.520 (0.114) Beta 31
Non-spine fracture 0.510 (0.150) Beta 31
Other treatment-related parameters
Persistence of treatment (probability at 1 year) 0.604 (0.071) Beta 33
Continuation of treatment effect following discontinuation of treatment (years) Declines over 5 years to zero Fixed 32
Mortality
Probability of all-cause death Age-specific
50 years of age 0.003 (0.0002) Beta 42
90 0.150 (0.005) Beta 42
Probability of death in year after hip fracture Age-specific
50 years of age 0.034 (0.002) Beta 25, 42
90 0.258 (0.009) Beta 25, 42
Cost ($ per patient per year, except where noted)
Intervention 44.34 (2.79) Gamma 19
BMD ($ per test) 119.12 Fixed 36
Bisphosphonate treatment 131.28 Fixed 35
Physician visit ($ per visit) 35.91 Fixed 36
Upper extremity fracture 1397 (70) Gamma 36, 38, 39
Upper extremity fracture post-pelvis fracture 13,854 (693) Gamma 36, 38–40
Spine fracture 1662 (83) Gamma 36, 38, 39
Spine fracture post-pelvis fracture 14,041 (702) Gamma 36, 38–40
Hip fracture 38,332 (1917) Gamma 36, 38–40
Late post-hip fracture cost 12,357 (618) Gamma 36, 38–40
Utility
General population utility score Age-specific
50–59 years 0.84 (0.013) Beta 25
60–69 years 0.82 (0.013) Beta 25
70–79 years 0.80 (0.018) Beta 25
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